Baseline characteristics of the subjects in the learning and validation cohorts
| . | Learning cohort* . | Validation cohort . | ||||||
|---|---|---|---|---|---|---|---|---|
| CMML† (n = 53) . | Aged-Co (n = 39) . | Non-CMML (n = 24) . | Reactive (n = 33) . | CMML† (n = 86) . | Aged-Co (n = 68) . | Non-CMML (n = 79) . | Reactive (n = 74) . | |
| Age, median y (range) | 78 (53-91) | 79 (62-94) | 74 (2-94) | 63.5 (36-87) | 77 (46-97) | 79.5 (50-92) | 73 (0.5-92) | 65 (37-91) |
| Gender, n (%) | ||||||||
| Male | 37 (70) | 13 (33) | 13 (54) | 20 (61) | 59 (69) | 16 (24) | 43 (55) | 40 (54) |
| Female | 16 (30) | 26 (67) | 11 (46) | 13 (39) | 27 (31) | 52 (76) | 36 (45) | 34 (46) |
| White blood cell count, median n × 109/L (range) | 9.25 (3.7-84.7) | 6.8 (4.9-16.4) | 7.4 (2.3-79.9) | 11.8 (4.7-33.4) | 9.3 (3.2-122.3) | 6.6 (4.6-9.9) | 5.7 (0.89-112.3) | 10.2 (4.2-658) |
| Hemoglobin, median g/dL (range) | 12.10 (7.5-14.9) | 12.8 (11.1-16.7) | 13.15 (8-26.8) | 10.6 (8-14.3) | 11.7 (6.1-16.9) | 13 (11.6-15.9) | 10.6 (5-18.2) | 10.7 (7.9-19) |
| Platelet count, median n × 109/L (range) | 86.5 (13-457) | 229 (156-406) | 207.5 (37-1045) | 298.5 (57-1143) | 132.5 (13-529) | 244 (129-443) | 151 (17-869) | 259 (7-1037) |
| Monocyte count, median n × 109/L (range) | 2.51 (1-28.8) | 0.62 (0.31-0.96) | 0.72 (0.2-2) | 1.3 (1.1-7) | 1.85 (1-60) | 0.6 (0.4-0.6) | 0.63 (0.11-21.98) | 1.4 (1-5.9) |
| CMML type 1/CMML type 2 | 48/5 | 63/11 | ||||||
| Low/intermediate/high cytogenetic risk, n | 41/5/1 | 45/5/6 | ||||||
| . | Learning cohort* . | Validation cohort . | ||||||
|---|---|---|---|---|---|---|---|---|
| CMML† (n = 53) . | Aged-Co (n = 39) . | Non-CMML (n = 24) . | Reactive (n = 33) . | CMML† (n = 86) . | Aged-Co (n = 68) . | Non-CMML (n = 79) . | Reactive (n = 74) . | |
| Age, median y (range) | 78 (53-91) | 79 (62-94) | 74 (2-94) | 63.5 (36-87) | 77 (46-97) | 79.5 (50-92) | 73 (0.5-92) | 65 (37-91) |
| Gender, n (%) | ||||||||
| Male | 37 (70) | 13 (33) | 13 (54) | 20 (61) | 59 (69) | 16 (24) | 43 (55) | 40 (54) |
| Female | 16 (30) | 26 (67) | 11 (46) | 13 (39) | 27 (31) | 52 (76) | 36 (45) | 34 (46) |
| White blood cell count, median n × 109/L (range) | 9.25 (3.7-84.7) | 6.8 (4.9-16.4) | 7.4 (2.3-79.9) | 11.8 (4.7-33.4) | 9.3 (3.2-122.3) | 6.6 (4.6-9.9) | 5.7 (0.89-112.3) | 10.2 (4.2-658) |
| Hemoglobin, median g/dL (range) | 12.10 (7.5-14.9) | 12.8 (11.1-16.7) | 13.15 (8-26.8) | 10.6 (8-14.3) | 11.7 (6.1-16.9) | 13 (11.6-15.9) | 10.6 (5-18.2) | 10.7 (7.9-19) |
| Platelet count, median n × 109/L (range) | 86.5 (13-457) | 229 (156-406) | 207.5 (37-1045) | 298.5 (57-1143) | 132.5 (13-529) | 244 (129-443) | 151 (17-869) | 259 (7-1037) |
| Monocyte count, median n × 109/L (range) | 2.51 (1-28.8) | 0.62 (0.31-0.96) | 0.72 (0.2-2) | 1.3 (1.1-7) | 1.85 (1-60) | 0.6 (0.4-0.6) | 0.63 (0.11-21.98) | 1.4 (1-5.9) |
| CMML type 1/CMML type 2 | 48/5 | 63/11 | ||||||
| Low/intermediate/high cytogenetic risk, n | 41/5/1 | 45/5/6 | ||||||
Age-Co, age-matched healthy donors; non-CMML, patients with diverse hematologic malignancies; Reactive, patients with reactive monocytosis.
The characteristics of young healthy donors (n = 26), who are voluntary blood donors, are unknown.
In these series, CMML patients were studied before any treatment.